Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders Volume 2, 2001 - Issue 3
Journal homepage
105
Views
18
CrossRef citations to date
0
Altmetric
Research Article

The Rilutek ® (riluzole) Global Early Access Programme: An open-label safety evaluation in the treatment of amyotrophic lateral sclerosis

Catherine Debove Aventis Pharma, 92165 Antony Cedex, France
,
Philippe Zeisser Aventis Pharma, 92165 Antony Cedex, France
,
Phyllis M Salzman Formerly Rhône-Poulenc Rorer
,
Larry K Powe Formerly Rhône-Poulenc Rorer
&
Philippe Truffinet Aventis Pharma, 92165 Antony Cedex, France
Pages 153-158 | Published online: 10 Jul 2009

  • Morris FH, Denys EH, Sang K, Mukai R The natural history of ALS in a specified population, with comments on risk factors, prognosis and symptomatic treatments. Gin Neurol 1989; 29: 1485-1492.
  • Williams DB, Windebank AJ. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Gin Proc 1991; 66: 54-82.
  • Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995; 68: 7-20.
  • Leigh PN, Meldrum BS. Excitotoxicity in ALS. Neurology 1996; 47 (suppl. 4): S221-S227.
  • Ince PG, Eggett C, Shaw PJ. The role of excitotoxicity in neurological disease. Rev Contemp Pharmacother 1997; 8: 195-212.
  • Doble A. The role of excitotoxicity in neurodegenerative disease: Implications for therapy. Pharmacol Ther 1999; 3: 163-221.
  • Gieramy A, Barbeito L, Codehue C, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992; 147: 209-212.
  • Debono M-W, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed by Xenopus oocytes. Eur J Pharmacol 1993; 235: 283-289.
  • Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CAl. Eur J Pharmacol 1993; 250: 473-476.
  • Hubert JP, Delumeau JC, Glowinsld J, Promont J, Doble A. Antagonism by riluzole of entry of calcium evoked by MNSA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol 1994; 113: 261-267.
  • Malgouris C, Daniel M, Doble A. Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices. Neurosd Lett 1994; 177: 95-99.
  • Couratier P, Sindou P, Esdaire F, Louvel E, Hugon J. Neuroprotective effects of riluzole in ALS CSF tcoddty. Neuroreport 1994; 5: 1012-1014.
  • Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996; 47 (suppl. 4): S233-S241.
  • Doble A. Effects of riluzole on glutamatergic neurotransmission in the mammalian central nervous system and other pharmacological effects. Rev Contemp Pharmacother 1997; 8: 213-226.
  • Bensimon C, Lacomblez L, Meininger V and the ALS/Riluzole study group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-591.
  • Lacomblez L, Bensimon C, Leigh PN, Guillet P, Meininger V, and the ALS/Riluzole study group II. Dose ranging study of riluzole in Amyotrophic Lateral Sclerosis. Lancet 1996; 347: 1425-1431.
  • World Federation of Neurology. Classification of Neuromuscular Disease. J Neurol Sd 1994; 124 (suppl), 96-107.
  • Department of Health and Human Services (DHSS). COSTART (Coding Symbols for Thesaurus of Adverse Reaction Terms) (3rd edn). Rockville, MD: DHHS, FDA, 1989.
  • Miller RG, Bouchard JP, Duquette P. Clinical trials of riluzole in patients with ALS. Neurology 1966; 4 (suppl 2) S86-S92.
  • Haas JF. The tolerability and adverse event profile of riluzole. Rev Contemp Pharmacother 1997; 8: 265-273.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.